Pfizer (NYSE: PFE) says it has reached 67 percent ownership of shares in Triangle-based Icagen (Nasdaq: ICGN) and is extending its $6 per share offer one last time.

The drug giant says it will pay Icagen investors to divest themselves of stock through Sept. 19. The deadline has been extended several times. The latest expired on Monday.

Pfizer has acquired more than 5 million shares in addition to the just over 1 million shares it already owned.

The company is paying $56 million to acquire Icagen.

Icagen will become part of a Pfizer subsidiary known as Eclipse Acquisition Corp.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.